Addressing Polycystic Ovary Syndrome in Pregnancy Care to Improve Outcomes
Mahnaz Bahri Khomami,Helena J. Teede
DOI: https://doi.org/10.1001/jamanetworkopen.2024.30549
2024-08-29
JAMA Network Open
Abstract:Polycystic ovary syndrome (PCOS) is a complex, multisystem condition that affects up to 13% of women of reproductive age. The 2023 International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome (2023 PCOS Guideline) 1 strongly recommends that clinicians recognize the notably higher risk for adverse pregnancy outcomes in women with PCOS and ensure proper identification of PCOS status early in pregnancy for appropriate monitoring and support throughout the pregnancy. Research in PCOS and pregnancy is limited by significantly poor capture of PCOS status during pregnancy, heterogeneity, and failure to account for confounders. There is a strong recommendation for greater research in these areas. The study by Talmo et al 2 in JAMA Network Open addresses some of these issues. Talmo et al 2 included data from 3 randomized clinical trials with well-characterized PCOS, ensuring consistent data collection and generating a larger cohort. The investigators considered potential confounders such as maternal age, parity, smoking status, marital status, educational level, and body mass index (BMI). For newborn anthropometric outcomes, they accounted for gestational age at birth and newborns' sex by calculating z scores. The cohort included singleton pregnancies in 390 women with PCOS and 68 708 women without PCOS. The findings confirm the 2023 PCOS guideline's results that newborns of women with PCOS are more likely to have lower birth weight, height, and head circumference, further exacerbated by increasing maternal BMI. Talmo et al 2 also compared hyperandrogenic and nonhyperandrogenic subgroups within the PCOS group and found no differences in newborn anthropometrics. Similarly, among those with and without gestational diabetes within the PCOS group, no differences in newborn anthropometrics were identified. However, the study did not explore the impact of hypertensive disorders of pregnancy on newborn anthropometrics. 2 PCOS has significant health implications, including increased risks for metabolic, dermatological, psychological, and reproductive complications. These include an elevated risk for overweight and obesity, type 2 diabetes, cardiovascular disease, hirsutism, acne, depression, anxiety, poor quality of life, subfertility, and pregnancy complications. 3 Globally, around 17 million pregnancies each year are affected by PCOS. Two meta-analyses, including 104 studies 4 and 73 studies 5 in pregnancy, found that compared with women without PCOS, those with PCOS had higher odds of miscarriage (with lower and upper limits of 95% CIs of 1.2 and 1.8 across studies), gestational diabetes (lower and upper limits of 95% CIs, 1.9 and 3.0), gestational hypertension (lower and upper limits of 95% CIs, 1.8 and 2.7), preeclampsia (lower and upper limits of 95% CIs, 1.9 and 2.8) cesarean section (lower and upper limits of 95% CIs, 1.1 and 1.4), preterm birth (lower and upper limits of 95% CIs, 1.3 and 1.7), fetal growth restriction (lower and upper limits of 95% CIs, 1.1 and 3.1), low birth weight (lower and upper limits of 95% CIs, 1.1 and 1.6). Despite the high prevalence and significant health effects of PCOS in pregnancy, as noted, research in this area remains inadequate. Research in PCOS and pregnancy faces substantial challenges related to the accurate assessment of PCOS status in both exposed and nonexposed groups, inconsistencies in the definition and timing of end point measurements, and the failure to account for confounders in study design or analysis. First, the inconsistency and variability in diagnostic criteria across studies can lead to heterogeneous data and complicate comparisons and meta-analyses. The 2023 PCOS Guideline, endorsed by 39 participating societies across 6 continents, requires the presence of at least 2 of 3 key features for diagnosis in adults: oligoanovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasonography or elevated anti-Müllerian hormone levels. This builds on the Rotterdam criteria, 6 which were applied by Talmo et al, 2 and extends them by further defining individual PCOS features and adding anti-Müllerian hormone. Second, many large-scale epidemiological datasets and pregnancy registries lack specific information on PCOS status, resulting in underreporting and potential misclassification. This issue is exacerbated by reliance on self-reported data, which may be subject to recall bias and inaccuracies. Third, the integration of clinical, biochemical, and ultrasonographic data necessary for a comprehensive PCOS diagnosis is often incomplete in existing population databases. This was highlighted in the study by Talmo et al, 2 where PCOS was not adequately recorded in the comparator group within the data regulated by the Norwegian H -Abstract Truncated-
medicine, general & internal